Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4139 Characterisation of new biomarkers from patients with neuroendocrine cancer using liquid biopsy methods

Introduction: Neuroendocrine tumors originate from neuroendocrine cells. Clinicians diagnose and track these tumors not only but also by analysing patients' blood for biomarkers. Including liquid biopsy in early detection and monitoring can improve patient outcomes.

Conference:

Presenting Author:

Authors: Pachnikova G, Jann H, Tacke F, Keilholz U,

Keywords: liquid biopsy, circulating tumor cells, cell-free DNA, neuroendocrine tumor, case study, copy number variations,

#4131 Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response

Introduction: Neuroendocrine neoplasms (NENs) are associated with poor health-related quality of life (HRQOL) due to tumor and hormonal related symptoms and treatment-related toxicity. Peptide receptor radionuclide therapy (PRRT) delivers targeted therapy for tumor and hormonal control.

Conference:

Presenting Author: Cehic G

Authors: Cehic G, Kong G, Corsini N, Chan D, Pavlakis N,

Keywords: PRRT, NENs, HRQOL,

#4088 Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs

Introduction: It is unknown whether tumor infiltrating lymphocytes (TILs) from NETs may be an effective treatment in patients with NETs.

Conference:

Presenting Author: Chaoul N

Authors: Chaoul N, d'Angelo G, Giglio A, Mandriani B, Matrella M,

Keywords: panNET, TILs, adoptive T cell therapy, neoantigen-reactive TILs,